Browsing by Author "Rylance S."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries
    (International Union Against Tuberculosis and Lung Disease, 2022) Stolbrink M.; Chinouya M.J.; Jayasooriya S.; Nightingale R.; Evans-Hill L.; Allan K.; Allen H.; Balen J.; Beacon T.; Bissell K.; Chakaya J.; Chiang C-Y.; Cohen M.; Devereux G.; El Sony A.; Halpin D.M.G.; Hurst J.R.; Kiprop C.; Lawson A.; Macé C.; Makhanu A.; Makokha P.; Masekela R.; Meme H.; Khoo E.M.; Nantanda R.; Pasternak S.; Perrin C.; Reddel H.; Rylance S.; Schweikert P.; Were C.; Williams S.; Winders T.; Yorgancioglu A.; Marks G.B.; Mortimer K.
    BACKGROUND: Access to affordable inhaled medicines for chronic respiratory diseases (CRDs) is severely limited in low- and middle-income countries (LMICs), causing avoidable morbidity and mortality. The International Union Against Tuberculosis and Lung Disease convened a stakeholder meeting on this topic in February 2022. METHODS : Focused group discussions were informed by literature and presentations summarising experiences of obtaining inhaled medicines in LMICs. The virtual meeting was moderated using a topic guide around barriers and solutions to improve access. The thematic framework approach was used for analysis. RESULT S : A total of 58 key stakeholders, including patients, healthcare practitioners, members of national and international organisations, industry and WHO representatives attended the meeting. There were 20 pre-meeting material submissions. The main barriers identified were 1) low awareness of CRDs; 2) limited data on CRD burden and treatments in LMICs; 3) ineffective procurement and distribution networks; and 4) poor communication of the needs of people with CRDs. Solutions discussed were 1) generation of data to inform policy and practice; 2) capacity building; 3) improved procurement mechanisms; 4) strengthened advocacy practices; and 5) a World Health Assembly Resolution. CONC L U S ION: There are opportunities to achieve improved access to affordable, quality-assured inhaled medicines in LMICs through coordinated, multi-stakeholder, collaborative efforts. © 2022 International Union against Tubercul. and Lung Dis.. All rights reserved.
  • No Thumbnail Available
    Item
    Key messages and partnerships to raise awareness and improve outcomes for people with asthma and COPD in low- and middle-income countries
    (International Union Against Tuberculosis and Lung Disease, 2022) Rylance S.; Bateman E.D.; Boulet L.; Cohen M.; Sony A.E.L.; Halpin D.M.G.; Khoo E.M.; Marks G.B.; Masekela R.; Mikkelsen B.; Mortimer K.J.; Muhwa J.C.; da Cunha I.N.; Šajnić A.; Salvi S.; Slama S.; Winders T.; Yorgancioglu A.; Zar H.J.
    [No abstract available]
  • No Thumbnail Available
    Item
    Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
    (BioMed Central Ltd, 2024) Lu W.; Aarsand R.; Schotte K.; Han J.; Lebedeva E.; Tsoy E.; Maglakelidze N.; Soriano J.B.; Bill W.; Halpin D.M.G.; Rivera M.P.; Fong K.M.; Kathuria H.; Yorgancıoğlu A.; Gappa M.; Lam D.C.L.; Rylance S.; Sohal S.S.
    The WHO recently published a Tobacco Knowledge Summary (TKS) synthesizing current evidence on tobacco and COPD, aiming to raise awareness among a broad audience of health care professionals. Furthermore, it can be used as an advocacy tool in the fight for tobacco control and prevention of tobacco-related disease. This article builds on the evidence presented in the TKS, with a greater level of detail intended for a lung-specialist audience. Pulmonologists have a vital role to play in advocating for the health of their patients and the wider population by sharing five key messages: (1) Smoking is the leading cause of COPD in high-income countries, contributing to approximately 70% of cases. Quitting tobacco is an essential step toward better lung health. (2) People with COPD face a significantly higher risk of developing lung cancer. Smoking cessation is a powerful measure to reduce cancer risk. (3) Cardiovascular disease, lung cancer and type-2 diabetes are common comorbidities in people with COPD. Quitting smoking not only improves COPD management, but also reduces the risk of developing these coexisting conditions. (4) Tobacco smoke also significantly impacts children’s lung growth and development, increasing the risk of respiratory infections, asthma and up to ten other conditions, and COPD later in life. Governments should implement effective tobacco control measures to protect vulnerable populations. (5) The tobacco industry’s aggressive strategies in the marketing of nicotine delivery systems and all tobacco products specifically target children, adolescents, and young adults. Protecting our youth from these harmful tactics is a top priority. © The Author(s) 2024.